↓ Skip to main content

Selinexor inhibits growth of patient derived chordomas in vivo as a single agent and in combination with abemaciclib through diverse mechanisms

Overview of attention for article published in Frontiers in oncology, August 2022
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (58th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter
5 X users

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
5 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Selinexor inhibits growth of patient derived chordomas in vivo as a single agent and in combination with abemaciclib through diverse mechanisms
Published in
Frontiers in oncology, August 2022
DOI 10.3389/fonc.2022.808021
Pubmed ID
Authors

Christopher J. Walker, Hua Chang, Leah Henegar, Trinayan Kashyap, Sharon Shacham, Josh Sommer, Michael J. Wick, Joan Levy, Yosef Landesman

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 5 100%

Demographic breakdown

Readers by professional status Count As %
Professor > Associate Professor 1 20%
Student > Bachelor 1 20%
Student > Master 1 20%
Unknown 2 40%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 2 40%
Neuroscience 1 20%
Unknown 2 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 August 2022.
All research outputs
#14,614,797
of 25,392,582 outputs
Outputs from Frontiers in oncology
#3,835
of 22,436 outputs
Outputs of similar age
#175,435
of 431,340 outputs
Outputs of similar age from Frontiers in oncology
#256
of 1,810 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,436 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 431,340 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.
We're also able to compare this research output to 1,810 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.